A Phase III, Open-Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Compared With Gemcitabine+Cisplatin or Carboplatin for PD-L1-Selected, Chemotherapy Naive Patients With Stage IV Squamous Non-Small Cell Lung Cancer
Phase of Trial: Phase III
Latest Information Update: 18 Apr 2018
At a glance
- Drugs Atezolizumab (Primary) ; Carboplatin; Cisplatin; Erlotinib; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Roche
- 17 Jan 2018 Status changed from active, no longer recruiting to completed.
- 12 Jan 2018 This trial has been completed in Poland.
- 04 Nov 2016 This trial was completed in Czech Republic, according to Eudra record.